VX-135 + daclatasvir

VX-135 + daclatasvir is a combination of two direct-acting antiviral (DAA) small molecules investigated for the treatment of hepatitis C virus (HCV) infection. **VX-135 (ALS-2200)** is a uridine nucleotide analogue inhibitor of the HCV NS5B polymerase, designed to inhibit viral RNA replication. **Daclatasvir (BMS-790052)** is a potent inhibitor of the HCV NS5A replication complex, involved in viral RNA replication and assembly. The combination targets two distinct steps in the HCV replication cycle, aiming for enhanced antiviral efficacy, and was developed as an interferon-free, all-oral regimen for chronic HCV infection, particularly genotypes 1 and 3. Clinical development reached phase 2 trials but did not proceed to approval[1][3][5].

Other names

VX-135 plus daclatasvirVX135 plus daclatasvirVX 135 plus daclatasvirALS-2200 plus daclatasvirALS2200 plus daclatasvirALS 2200 plus daclatasvirdaclatasvir plus VX-135BMS-790052 plus VX-135BMS790052 plus VX-135BMS 790052 plus VX-135